West Pharmaceutical Services (NYSE:WST) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS

West Pharmaceutical Services (NYSE:WST) issued its quarterly earnings data on Thursday. The medical instruments supplier reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.75 by $0.07, Zacks reports. West Pharmaceutical Services had a net margin of 17.37% and a return on equity of 18.41%. West Pharmaceutical Services updated its FY 2025 guidance to 6.000-6.200 EPS.

West Pharmaceutical Services Trading Up 7.9 %

West Pharmaceutical Services stock traded up $15.73 during mid-day trading on Friday, hitting $214.84. 5,020,477 shares of the stock were exchanged, compared to its average volume of 424,824. The company has a quick ratio of 2.23, a current ratio of 3.00 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a 12 month low of $197.01 and a 12 month high of $400.88. The firm’s fifty day simple moving average is $327.86 and its two-hundred day simple moving average is $313.82. The stock has a market capitalization of $15.56 billion, a price-to-earnings ratio of 31.87, a PEG ratio of 19.31 and a beta of 1.01.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, February 11th. Shareholders of record on Friday, February 7th were issued a dividend of $0.21 per share. The ex-dividend date of this dividend was Friday, February 7th. This represents a $0.84 annualized dividend and a yield of 0.39%. West Pharmaceutical Services’s payout ratio is 12.46%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. KeyCorp reduced their price target on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating on the stock in a research note on Friday. UBS Group upgraded shares of West Pharmaceutical Services from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $350.00 to $390.00 in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 target price on the stock in a research report on Friday. Wolfe Research initiated coverage on shares of West Pharmaceutical Services in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. Finally, Bank of America lifted their target price on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $344.00.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.